Case 2: Antiretroviral Regimens for Initial Therapy - Antiretroviral Rx

Case-Based Modules
Initial Evaluation
Dermatologic Manifestations
Oral Manifestations
OIs: Prophylaxis
OIs: Treatment
Antiretroviral Rx
Antiretroviral Rx: Resistance
Antiretroviral Rx: Adverse Effects
Drug-Drug Interactions
Postexposure Prophylaxis
Perinatal Transmission
Special Populations
Prevention for Positives
Challenging Unknowns
Interactive Tutorials
This program is funded through Health Resources and Services Administration, US Department of Health and Human Services.

Home
About This Site
Free CME
AETC NRC
Resources
Feedback
Site Map
Authors

Question | Discussion | References | CME Credit

Case 2: Antiretroviral Regimens

You answered:

	Abacavir (Ziagen) plus tenofovir (Viread) plus lamivudine (Epivir) is considered an alternative regimen.

This answer is incorrect. The use of abacavir plus tenofovir plus lamivudine as a three-drug regimen is an antiretroviral regimens that should not be offered at any time. This recommendation is based on several studies that showed an unacceptably high virologic failure rate with this regimen.

	Zidovudine-lamivudine (Combivir) plus efavirenz (Sustiva) is considered a preferred regimen.
	Tenofovir-emtricitabine (Truvada) plus ritonavir (Norvir) plus darunavir (Prezista) is considered a preferred regimen.
	Stavudine (Zerit) plus lamivudine (Epivir) plus lopinavir-ritonavir (Kaletra) is considered a preferred regimen.

[Back to Case 2 Question | Go to Correct Answer]